SURVIVIN AND CK2 CO-EXPRESSION IN HUMAN PROSTATE CANCER -

Objective: To check the co-expression of survivin and CK2 in prostate cancer patients as compared to the Benign Prostatic Hyperplasia (BPH) patients. Study Design: Cross-sectional analytical study. Place and Duration of Study: This study was conducted at Armed Forces Institute of Pathology, Army Medical College Rawalpindi, from Dec 2012 to April 2014. Material and Methods: The study was designed as a cross-sectional analytical study and conducted at Armed Forces Institute of Pathology, Army Medical College Rawalpindi, from Dec 2012 to April 2014, after approval from institutional ethical committee. Expression of survivin was analyzed by immunostaining in paraffin-embedded sections from 30 diagnosed cases of resected prostate cancer and 30 BPH cases that were also immune stained for CK2. Results: The CK2 and survivin were found to overexpress in prostate cancer as compared to BPH. Total score of CK2 survivin were strongly positive and significantly correlated in non-invasive cases as compared to BPH. Conclusion: There is a strong positive correlation between survivin and CK2 over-expression in prostate cancer patients specifically non-invasive cases suggesting the coordination between the two proteins in early stages of prostate cancer progression.

[1]  F. Ringeisen,et al.  Nuclear localization of protein kinase CK2 catalytic subunit (CK2alpha) is associated with poor prognostic factors in human prostate cancer. , 2007, European journal of cancer.

[2]  James S. Duncan,et al.  Protein kinase CK2 is a constitutively active enzyme that promotes cell survival: strategies to identify CK2 substrates and manipulate its activity in mammalian cells. , 2010, Methods in enzymology.

[3]  K. Schaser,et al.  Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients , 2010, BMC Cancer.

[4]  M. Montenarh,et al.  CK2 inhibition induces apoptosis via the ER stress response. , 2011, Cellular signalling.

[5]  S. Yu,et al.  Protein kinase CK2 signal in neoplasia. , 2001, Histology and histopathology.

[6]  C. Van Waes,et al.  Emergence of protein kinase CK2 as a key target in cancer therapy , 2010, BioFactors.

[7]  D. Litchfield,et al.  Assembly of protein kinase CK2: investigation of complex formation between catalytic and regulatory subunits using a zinc-finger-deficient mutant of CK2beta. , 2001, The Biochemical journal.

[8]  Salma Khan,et al.  Early diagnostic value of survivin and its alternative splice variants in breast cancer , 2014, BMC Cancer.

[9]  C. Allende,et al.  Protein kinase CK2: an enzyme with multiple substrates and a puzzling regulation , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.